Positive safety and pharmacokinetic data lay foundation for phase 2 study in 2026
Category: News
New survey reveals critical gaps in access to testing and timely care
Six new treatments aim to improve patient outcomes across key areas
UPSIDE study explores early transplant therapy for rare autoimmune disease
Early-stage study reveals strong immune response and safety profile for ACI-35.030
EU phase 3 data shows major gains in dialysis access performance
Acella and Neuvosyn report positive results for investigational DTE therapy
GM CRDC begins trials to assess real-world effectiveness of respiratory vaccines
CHMP backs AstraZeneca and Amgen’s therapy for chronic rhinosinusitis
EMA opinion supports expanded use of TREMFYA in phase 3 UC treatment